What Is the Best Antibiotic for Sepsis?

There is no single best antibiotic for sepsis. The right drug depends on where the infection started, which organism is causing it, how sick the patient is, and what resistance patterns look like locally. What the evidence consistently shows is that giving an appropriate antibiotic quickly is more important than choosing any one particular drug. Each hour of delay in antibiotic administration raises in-hospital mortality by roughly four percent, and the penalty climbs steeply in patients who are already in shock.

Why Timing Outweighs the Choice of Drug

The question most people ask is “which antibiotic?” but the question that saves the most lives is “how fast?” A large meta-analysis found that every hour antibiotics were delayed past the first hour increased in-hospital mortality, with an odds ratio of about 1.04 per hour and a roughly 20 percent higher odds of dying when treatment started after one hour compared with within one hour.¹ A separate systematic review confirmed that the benefit of early antibiotics was strongest in patients with shock, where giving drugs within three hours cut mortality risk significantly compared with waiting longer.²

A multicenter study of emergency department patients put numbers on each severity tier. For patients with sepsis but no shock, each hour of delay added about 0.3 percent to absolute mortality. For severe sepsis, that figure rose to 0.4 percent per hour. For septic shock, it jumped to 1.8 percent per hour.³ In practical terms, a patient in septic shock who waits three extra hours has lost roughly five percentage points of survival compared to one treated immediately.

Current Surviving Sepsis Campaign guidelines reflect this with a risk-stratified approach. Patients in shock should receive antibiotics within an hour. Patients who look less critically ill and whose infection is only suspected rather than certain have a wider window, up to three hours, giving clinicians time to gather cultures and avoid unnecessary treatment. A real-world analysis found that this lower-acuity group had a median time to antibiotics of about five and a half hours and only 2 percent mortality, supporting the idea that a one-hour mandate for everyone is unnecessarily aggressive.⁴

The Most Common Empiric Regimens

Because blood culture results take a day or more to come back, doctors start with “empiric” antibiotics, meaning drugs chosen to cover the likeliest organisms before anyone knows exactly what is causing the infection. A study of nearly 900,000 U.S. hospital admissions for suspected community-onset sepsis found that the most prescribed empiric drug was vancomycin, given to about 41 percent of patients, followed by ceftriaxone at roughly 38 percent, piperacillin-tazobactam at 31 percent, and cefepime at about 25 percent.⁵ About two-thirds of those patients received at least one drug aimed at resistant gram-negative bacteria or MRSA.

Vancomycin covers MRSA and other resistant gram-positive organisms. It is usually paired with a broad-spectrum beta-lactam (like piperacillin-tazobactam, cefepime, or meropenem) that handles gram-negative bacteria. Ceftriaxone, a narrower-spectrum drug, is common for less critically ill patients with suspected community-acquired infections like pneumonia or urinary tract infections. The choice between these drugs reflects the patient’s illness severity, the suspected source, and the local resistance landscape far more than it reflects one drug being inherently superior.

Piperacillin-Tazobactam Versus Cefepime

One of the hottest debates in sepsis care is whether piperacillin-tazobactam or cefepime should be the default broad-spectrum empiric drug. These two are prescribed in roughly similar situations, so comparing them matters. An instrumental-variable analysis of patients with suspected sepsis found that piperacillin-tazobactam was associated with a five-percentage-point increase in 90-day mortality compared with cefepime, along with more days on ventilators and vasopressors.⁶ The authors suggested that the anti-anaerobic activity of piperacillin-tazobactam, while useful for abdominal infections, may disrupt beneficial gut bacteria in patients who do not need that coverage, potentially causing harm.

However, another analysis using a different hospital database found no significant difference in 90-day mortality between the two drugs, and similar rates of complications like C. difficile infection.⁷ A more recent study added an interesting wrinkle: in patients with high white blood cell counts (above 16,000), piperacillin-tazobactam was actually associated with lower mortality than cefepime, suggesting the “better” drug may depend on the patient’s inflammatory state.⁸ The upshot is that neither drug is categorically superior. The choice hinges on whether the patient has an infection source (like the abdomen) that needs anti-anaerobic coverage, and possibly on features like white cell count that are still being studied.

Matching the Drug to the Infection Source

Once there is a clue about where the infection started, the antibiotic strategy narrows considerably. A few common patterns illustrate why “best antibiotic” is never a universal answer.

For intra-abdominal infections, such as a perforated bowel or abscess, the organisms involved are predictably a mix of gram-negative bacteria and anaerobes. Treatment therefore must cover both.⁹ Drugs like piperacillin-tazobactam or a carbapenem fill this role well, and source control (draining the abscess, repairing the perforation) matters as much as the antibiotic itself.

For urinary-source sepsis, the dominant organisms are typically gram-negative rods like E. coli. The choice of empiric drug should factor in whether the infection was acquired in the community or in a hospital, any prior antibiotic use, and local resistance surveillance data.¹⁰ A community-acquired urinary infection in someone with no recent antibiotic use might respond fine to ceftriaxone, while a hospital-acquired one in a patient recently on antibiotics might need a carbapenem.

For septic shock caused by Candida (a fungus, not a bacterium), antibiotics are useless. Antifungal drugs are required, and the stakes for delay are extreme. A study found that when antifungal therapy and source control were both achieved within 24 hours, hospital mortality was about 53 percent, which is already grim. When those goals were missed, mortality climbed to nearly 98 percent.¹¹ Patients at high risk for fungal sepsis, such as those on prolonged broad-spectrum antibiotics, with central lines, or with recent abdominal surgery, are candidates for empiric antifungal coverage.

When Combination Therapy Helps

Many sepsis patients receive more than one antibiotic simultaneously. The logic is simple: using two drugs from different classes increases the odds of hitting the right organism before culture results arrive. A retrospective analysis of gram-negative sepsis found that patients given a beta-lactam plus either an aminoglycoside or a fluoroquinolone were more likely to receive appropriate initial therapy compared with those on a single drug.¹²

The benefit of combination therapy is clearest in the highest-risk patients. A multicenter study of bloodstream infections caused by carbapenem-resistant gram-negative bacteria found that combination therapy did not improve survival overall compared with a single appropriate drug. But in the subset of patients with septic shock, and in those who received combination therapy within 48 hours of infection, survival was significantly better.¹³ This matches the general principle: the sicker the patient and the more resistant the organism, the more combination therapy matters.

How Sepsis Changes Drug Behavior in the Body

A drug that works at normal doses in a healthy person may fail at the same doses in a septic patient. Sepsis causes leaky blood vessels, shifts in blood flow, changes in protein levels, and swings in kidney function, all of which alter how antibiotics distribute through the body and how fast they are cleared.¹⁴ In the early phase, fluid resuscitation expands blood volume, diluting drugs that dissolve in water (which includes most beta-lactams and aminoglycosides). Later, as organs fail, drugs may accumulate to toxic levels. Patients on kidney replacement therapy present a particular dosing challenge, and monitoring drug levels in the blood is strongly recommended for drugs with a narrow margin between effective and toxic doses.¹⁵

One practical response to this problem is extended or continuous infusion of beta-lactam antibiotics, where the drug drips in over several hours instead of being pushed in over 30 minutes. The goal is to keep blood levels above the threshold needed to kill bacteria for a longer fraction of the dosing interval. A meta-analysis of over 9,000 sepsis patients found that continuous infusion was associated with lower hospital mortality, higher clinical cure rates, and improved survival at the end of follow-up compared with standard intermittent dosing.¹⁶ A separate study found that extended infusion lowered the odds of death by about 29 percent, though the benefit was concentrated in patients who were severely ill or whose bacteria were on the edge of resistance.¹⁷ Extended infusion is increasingly standard practice in ICUs, though it does come with higher rates of line complications and certain adverse events.

The Kidney Injury Problem

One of the most well-documented harms in sepsis antibiotic selection is the combination of vancomycin with piperacillin-tazobactam, which raises the risk of acute kidney injury well above what either drug causes alone or what vancomycin causes when paired with other beta-lactams. A network meta-analysis found that vancomycin plus piperacillin-tazobactam carried roughly two and a half times the odds of kidney injury compared with vancomycin plus cefepime, and about twice the odds compared with vancomycin plus meropenem.¹⁸ The elevated risk held up in critically ill patients and in children. A separate meta-analysis confirmed the finding, showing about double the odds of kidney injury with the vancomycin-piperacillin-tazobactam combination versus vancomycin-meropenem.¹⁹

Because vancomycin is the most commonly prescribed empiric antibiotic in U.S. sepsis care and piperacillin-tazobactam is the third most common, a huge number of patients are receiving this combination. Many hospitals have started shifting to vancomycin plus cefepime or vancomycin plus meropenem as default pairings to reduce kidney damage, particularly in patients who already have impaired renal function or are receiving other drugs that stress the kidneys.

Drug-Resistant Infections and the Narrowing Pipeline

The hardest sepsis cases involve organisms that resist the standard empiric drugs, particularly carbapenem-resistant gram-negative bacteria. Carbapenems like meropenem are often considered the last-resort beta-lactams; when bacteria defeat them, treatment options thin out dramatically. Several newer drugs have been developed to address this gap, including beta-lactam combinations like ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, and the siderophore cephalosporin cefiderocol.²⁰

Even among these newer agents, there are blind spots. Bacteria that produce metallo-beta-lactamases, a type of resistance enzyme especially common in parts of Asia and Latin America, are not well covered by most of the newer beta-lactam combinations. Treatment options for those infections remain limited.²¹ This is why local resistance surveillance matters so much: a hospital in a region where metallo-beta-lactamase producers are rare will choose different empiric regimens than one where they are endemic.

Rapid Diagnostics and Knowing When to Stop

The flip side of starting antibiotics fast is knowing when to narrow or stop them. Broad-spectrum empiric therapy is a necessary gamble at the outset, but every unnecessary day of broad-spectrum drugs increases the risk of C. difficile infection, promotes resistance, and adds potential for drug toxicity. Two developments are changing how quickly clinicians can make those decisions.

The first is rapid molecular diagnostic technology. Traditional blood cultures take one to three days to identify an organism and test its drug susceptibilities. Newer platforms can detect pathogens and resistance genes directly from a blood sample in hours. A systematic review found that these tools improved the appropriateness of antibiotic therapy, and in one application, appropriate antifungal therapy was initiated six hours after blood draw rather than the 32 hours typical with conventional cultures.²² A comparative study in an ICU found that antibiotic therapy was changed in 60 percent of patients whose rapid molecular test came back positive, beating conventional culture results by a median of more than 100 hours.²³

The second is procalcitonin-guided de-escalation. Procalcitonin is a blood marker that rises during bacterial infection and falls as infection resolves. A randomized trial found that using procalcitonin to guide antibiotic stopping nearly halved the duration of therapy, from a median of nine days in the standard-care group to about five days in the procalcitonin-guided group, with no increase in deaths or recurrent infections.²⁴ Similar results have been seen in cancer patients with febrile neutropenia, where a procalcitonin drop triggered earlier de-escalation of intravenous antibiotics and shortened therapy duration.²⁵

Special Populations That Change the Calculus

Certain patient groups need a fundamentally different approach to empiric antibiotic selection, not just a dose adjustment.

Patients with cancer and very low white blood cell counts (neutropenic fever) are at extreme risk for rapid deterioration. European guidelines recommend that hemodynamically stable patients without known resistant organisms can start with a single anti-pseudomonal beta-lactam, avoiding carbapenems and newer agents to preserve them. But critically ill neutropenic patients, or those colonized with resistant bacteria, need broader-spectrum regimens: a beta-lactam plus aminoglycoside, a carbapenem, or newer combinations like anti-pseudomonal cephalosporin with a beta-lactamase inhibitor, tailored to local epidemiology.²⁶ A hospital in a region with high carbapenem resistance will necessarily choose differently than one where resistance rates are low.

Pregnant patients present another set of challenges. The physiological changes of pregnancy, including increased blood volume, altered kidney filtration rates, and changes in drug metabolism, affect how antibiotics perform. Diagnosing sepsis itself is harder, because pregnancy naturally raises heart rate and white blood cell count, mimicking some of the signs clinicians rely on to identify infection. Drug safety for the fetus adds another constraint, ruling out certain antibiotics that would otherwise be first-line choices.²⁷

MRSA Coverage and Whether Everyone Needs It

Vancomycin is the workhorse for suspected MRSA infections, and as the most commonly prescribed empiric antibiotic in U.S. sepsis care, it is clearly being used broadly. But evidence is emerging that not every sepsis patient needs empiric MRSA coverage. A modeling study found that vancomycin works adequately against MRSA strains with lower levels of resistance but fails against strains at higher resistance thresholds, suggesting that the drug’s reputation as a reliable catch-all is shakier than many clinicians assume.²⁸

Some hospitals are already rethinking blanket empiric vancomycin. One institution revised its guidelines for patients with blood cancers and neutropenic fever who had a history of MRSA colonization but no active MRSA bloodstream infection, moving toward a delayed-prescription approach where vancomycin is added only if microbiology results or clinical deterioration warrant it.²⁹ Given the kidney injury risks of vancomycin-containing combinations, being more selective about who gets it could reduce harm without sacrificing coverage for patients who truly need it.